Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563524 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
A Phase 1 study of Psoriasis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT00563524: Completed Phase 1 study of Psoriasis, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00563524 is a Phase 1 study of Psoriasis that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 76 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00563524, a Phase 1 study of Psoriasis, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
Primary Outcome
An AE was any untoward medical occurrence attributed to a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the
Conditions Studied
Interventions
- DRUG ILV-094
Study Locations (20)
Indiana
- Hudson Dermatology - Evansville
- Dawes Fretzin Clinical Research Group - Indianapolis
- Dawes Fretzin Dermatology Group - Indianapolis
Alberta
- Stratical Medical - Edmonton
- University of Alberta, Hospital Site Clinical Sciences Building - Edmonton
- The Northern Alberta Clinical Trials and Research Centre (NACTRC) - Edmonton
California
- David Stoll, MD - Beverly Hills
- Dermatology Research - Santa Monica
Florida
- Miami Research Associates - South Miami
- MRA Clinical Research - South Miami
New York
- New York University Medical Center - New York
- Mount Sinai School of Medicine - New York
Ontario
- Bio Pharma Services Inc - Toronto
- K. Papp Clinical Research - Waterloo
Michigan
- Hamzavi Dermatology - Fort Gratiot
Missouri
- Central Dermatology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-12-20 |
| Est. Completion | 2010-06-14 |
| Phase | Phase 1 |
What the finished NCT00563524 record still lists
NCT00563524 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ILV-094 is the first listed.
NCT00563524 names 20 study sites across 12 states, led by Indiana, Alberta, California.
Frequently Asked Questions
What is clinical trial NCT00563524 about?
NCT00563524 is a clinical study titled "Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis". The purpose of this study is to assess safety, and tolerability of multiple doses of ILV-094 administered to subjects with psoriasis
What is the current status of trial NCT00563524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2007-12-20. Estimated completion is 2010-06-14.
What conditions does trial NCT00563524 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00563524?
The interventions under investigation include: ILV-094 (DRUG).
Who is sponsoring clinical trial NCT00563524?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00563524 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00563524's enrollment target sits among peer trials
76 65th of 125 higher than 61 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI